![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preclinical characterization of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Jacobson1, M Feese1, H Xiao1, E Sanchez1, L Uher1, B Lin1, R Tomkiewicz1, T Whitaker2, T McBrayer2, L Pascual2, J Pattassery2, S Lee1 1 Cocrystal Pharma Inc., Bothell, WA 98011 and 2 Cocrystal Pharma Inc., Tucker, GA 30084
![AASLD1.gif](../images/112315/112315-4/AASLD1.gif)
![AASLD2.gif](../images/112315/112315-4/AASLD2.gif)
![AASLD3.gif](../images/112315/112315-4/AASLD3.gif)
![AASLD4.gif](../images/112315/112315-4/AASLD4.gif)
![AASLD5.gif](../images/112315/112315-4/AASLD5.gif)
![AASLD6.gif](../images/112315/112315-4/AASLD6.gif)
![AASLD7.gif](../images/112315/112315-4/AASLD7.gif)
![AASLD8.gif](../images/112315/112315-4/AASLD8.gif)
![AASLD9.gif](../images/112315/112315-4/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|